In contrast, camrelizumab, toripalimab, serplulimab and tislelizumab have shown efficacy that is independent of PD-L1 expression, with positive outcomes observed in ESCC patients across all PD-L1 expression levels. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.